Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

The Two-State Receptor Model01:29

The Two-State Receptor Model

1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
1.9K
Cooperative Allosteric Transitions01:58

Cooperative Allosteric Transitions

7.8K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
7.8K
Allosteric Regulation01:08

Allosteric Regulation

57.5K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
57.5K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

2.6K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
2.6K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

2.3K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.3K
Drug-Receptor Interactions01:29

Drug-Receptor Interactions

4.8K
Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
4.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

High throughput, automated and fully contained cytokine release assay using primary human CD4<sup>+</sup> T cells.

SLAS discovery : advancing life sciences R & D·2026
Same author

Discovery of an ITK and TRK kinase inhibitor for the potential topical treatment of atopic dermatitis.

Nature communications·2026
Same author

The limitations of small molecule and genetic screening in phenotypic drug discovery.

Cell chemical biology·2025
Same author

Discovery of PF-07054894, a Potent Squaramide-Based CCR6 Antagonist Displaying High CXCR2 Selectivity.

Journal of medicinal chemistry·2025
Same author

Peptidylarginine Deiminase (PAD) Inhibitor Optimization through Displacement of a Trapped Water Molecule.

ACS medicinal chemistry letters·2025
Same author

Inhibiting peptidylarginine deiminases (PAD1-4) by targeting a Ca<sup>2+</sup> dependent allosteric binding site.

Nature communications·2025

相关实验视频

Updated: May 24, 2025

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.8K

了解CXCR2对抗性与动态全三元复合体模型的理解.

Rui Li1, Richard Frisbie2, Fabien Vincent2

  • 1Pharmacokinetics, Dynamics & Metabolism, Pfizer Inc, Cambridge, Massachusetts.

The Journal of pharmacology and experimental therapeutics
|March 1, 2025
PubMed
概括

CXC化学因子受体2 (CXCR2) 抗体表现出可变的抗性. 一个动态的全模型解释了这些差异,将体外数据与CXCR2抗剂和其他受体的临床结果联系起来.

关键词:
艾洛斯特的对抗主义.CXCR2CXCR2CXCR2CXCR2CXCR2CXCR2CXCR2C动态全三元复合模型模型.在 PKPD 建模中,PKPD 建模是:

更多相关视频

Optimizing the Genetic Incorporation of Chemical Probes into GPCRs for Photo-crosslinking Mapping and Bioorthogonal Chemistry in Live Mammalian Cells
14:02

Optimizing the Genetic Incorporation of Chemical Probes into GPCRs for Photo-crosslinking Mapping and Bioorthogonal Chemistry in Live Mammalian Cells

Published on: April 9, 2018

8.4K
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.2K

相关实验视频

Last Updated: May 24, 2025

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators
07:41

A Kinetic Fluorescence-based Ca2+ Mobilization Assay to Identify G Protein-coupled Receptor Agonists, Antagonists, and Allosteric Modulators

Published on: February 20, 2018

8.8K
Optimizing the Genetic Incorporation of Chemical Probes into GPCRs for Photo-crosslinking Mapping and Bioorthogonal Chemistry in Live Mammalian Cells
14:02

Optimizing the Genetic Incorporation of Chemical Probes into GPCRs for Photo-crosslinking Mapping and Bioorthogonal Chemistry in Live Mammalian Cells

Published on: April 9, 2018

8.4K
Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes
07:22

Author Spotlight: Evaluating Biophysical Assays for Characterizing PROTACS Ternary Complexes

Published on: January 12, 2024

3.2K

科学领域:

  • 药理学 药理学是指药理学的学科.
  • 生物化学 生化学
  • 药物发现 药物发现 药物发现

背景情况:

  • CXC化学因子受体2 (CXCR2) 抗体在体外和临床研究中表现出不同的抗性模式.
  • 现有的CXCR2抗剂是全osteric,但显示不一致的测定结果和临床疗效.
  • 在临床试验中有利的药物暴露与观察到的标调制和疗效问题形成对比.

研究的目的:

  • 使用动态全三元复合模型阐明不一致的CXCR2抗剂行为的机制基础.
  • 统一解释不同实验环境中观察到的可变对抗模式的假设.
  • 为了弥合CXCR2抗剂的体外药理学和临床结果之间的差距.

主要方法:

  • 应用动态全三元复合模型来分析体外结合和基于细胞的测试数据.
  • 使用拟议模型分析CXCR2抗剂研究中的临床中性粒细胞计数数据.
  • 基于受体储备和结合动力学,开发一个统一的假设来解释可克服与不可克服的对抗性.

主要成果:

  • 动态全三元复合模型成功地描述了CXCR2抗剂的体外和临床数据.
  • 在基于细胞的测定中,不一致的对抗性模式归因于受体储备和不稳定状态的结合.
  • 在某些情况下,低于最佳的功效,而不是快速结合动力学,可能解释了临床药理学效应的缺乏.

结论:

  • 拟议的模型为CXCR2抗剂的可变药理学提供了统一的解释.
  • 受体储备和结合动力学是影响不同测试条件下对抗性行为的关键因素.
  • 该模型提供了一个框架,用于预测CXCR2和其他GPCRs的全抗体的临床反应.